Clinical Trial Update: ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of ZK-Epo in combination with carboplatin for recurrent ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• ZK-Epo (unknown)

Snippet

Sponsor: Bayer | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED